Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Business Update

Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax


Following to the previous information on March 11th, 2024, we are excited to share our latest development status.

We are pleased to announce the protocol for the Phase I/II clinical trial of DFP-10917 combined with Venetoclax (VTX) in patients with acute myeloid leukemia (AML) with prior VTX involved one regimen, which was submitted to the FDA in US on March 8 has been approved by the FDA in US dated April 8, 2024. Accordingly, we can start the Phase I/II combo-study very soon.

The aim for conducting this study is to judge if DFP-10917 combined with VTX is to show superiority to the standard chemotherapy (azacitidine combined with VTX) for AML. This combo-study shall be done by major clinical sites in US like Wake Forest University, expertise with clinical study of novel chemotherapy for AML.

The interim analysis of the Phase III trial of DFP-10917 monotherapy in patients with recurrent or refractory AML is under follow-up for a number of long-term survivors that have a significant impact on the overall survival (OS) analysis.?

Please take notice of our own innovative approach for miserable cancer patients and contact with us.


These press releases may also interest you

at 16:10
Agilysys to Report Fiscal 2024 Fourth Quarter Results May 13th and Host Conference Call and Webcast
Agilysys, Inc. , a leading global provider of hospitality software solutions and services that deliver High Return Hospitality, announced today that it will release its fiscal 2024 fourth quarter results after the market closes on Monday, May 13,...

at 16:10
CareDx to Report First Quarter 2024 Financial Results
CareDx, Inc. ? The Transplant Companytm focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers ? today announced it will report financial...

at 16:10
Sensata Technologies Reports First Quarter 2024 Financial Results
Sensata Technologies , a global industrial technology company and leading provider of sensors, sensor-rich solutions and electrical protection devices used in mission-critical systems that create valuable business insights for customers, today...

at 16:10
F5 Reports Strong Earnings Growth in its Second Quarter of Fiscal Year 2024; Raises Fiscal Year 2024 Earnings Outlook
F5, Inc. today announced financial results for its second quarter ended March 31, 2024. "We delivered a solid second quarter, with revenue near the midpoint of our guidance range and earnings per share at the high end of our guidance in an...

at 16:10
Chegg Reports 2024 First Quarter Earnings
Chegg, Inc. , the leading student-first connected learning platform, today reported financial results for the three months ended March 31, 2024. "Nathan has been core to Chegg's success from our earliest days as a textbook rental company, to...

at 16:10
Blend Labs Announces Strategic Partnership with Haveli Investments, including $150 Million Investment
Blend Labs, Inc. , ("Blend" or the "Company"), a leading provider of cloud banking services, and Haveli Investments ("Haveli"), a technology-focused private equity firm, today announced a $150 million investment in the Company by Haveli Investments...

More news about Science and technology...


News published on and distributed by: